- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03477240
Feasibility Study Of A Telephonic Questionnaire For Follow-Up Of Locally Advanced Cervical Cancer Patients
A Cross-Sectional Feasibility Study of a Telephonic Questionnaire By Research Nurses For Follow-Up Of Locally Advanced Cervical Cancer Patients With Complete Response To Treatment.
Descripción general del estudio
Estado
Descripción detallada
Our institution registers on an average 670 cases of cancer cervix in a year and almost 75% are treated with curative intent, therefore around 500 patients a year would be treated with curative intent. Assuming that 75% of patients registered in a year would be receiving treatment at our institute, 375 patients a year would be completing treatment, of whom the investigator expect 80-85% ,i.e 300 patients to have a complete response. The list of patients who have completed radio(chemotherapy) in 2015 &2016 can be obtained from the Radiation Oncology Department records. Patients identified for a follow up visit will be telephonically contacted between one and two weeks before the planned clinic visit and verbal telephonic consent taken prior to the nurse-led interview. This study should be able to accrue 300 patients in 6 months.
Patients of locally advanced cervical cancer or vault cancer who have been treated with radiotherapy with or without concurrent chemotherapy and have a clinical complete response at 3 months post treatment and are within the first 2 years post treatment completion will be eligible to participate in this study.
Screening: Patients will be screened from the list of patients treated in the radiotherapy department over the last 2 years (2015-2016), available from the Radiation Oncology Information System (ROIS). All patients with a diagnosis of cervical cancer or vault cancer will be screened using the hospital Electronic Medical Record (EMR) to check stage of disease, schedule of treatment received, response at 3 months post treatment and expected date of next follow up.
If patient fulfils all inclusion criteria, she will be called by the research nurse, approximately 1-2 weeks prior to her expected date of follow up, for a preliminary conversation and invited to participate in the study.
After verbal telephonic consent is obtained, she will be interviewed by the clinical research nurse using the format of the prepared proforma (Form A) regarding symptoms suggestive of disease recurrence as well as treatment induced toxicity. At the end of the interview, the research nurse records her impression of whether the patient has worrisome symptoms of disease or not and has symptoms of treatment toxicity or not for which she should visit the hospital.
When the patient reports to the OPD the next week for scheduled physical follow up, the nurse completes the consenting process by taking a short written informed consent. The examining physician then takes a complete history and in addition, performs a physical examination and any investigations he/she deems necessary. Following this he/she notes down final impression of disease status and toxicity which are taken as the gold standard (Form B). Each patient will be interviewed only once during their follow up schedule.
In addition at the physical visit, information regarding the acceptability of nurse-led telephonic follow-up to the patient and the financial impact of physical follow- up will be collected using a structured format (Form C).
Study participant drop-out/ Lost-to-follow up: Patients may withdraw their consent at any point during the telephonic interview or the subsequent follow up visit.
- A patient who does not attend the scheduled follow up visit within 1-2 weeks of the telephonic interview will be called a second time to remind her of the follow up appointment and enquire about reasons for non-attendance in the clinic, which will be recorded. If patient does not report to the clinic within the next 2 weeks, she will be considered to have dropped out from the study.
- Those patients in whom the interval between telephonic interview and the physician's assessment is more than 4 weeks, will be considered drop outs and follow up telephone call will go out to enquire about reasons for non-attendance in the clinic, which will be recorded.
Tipo de estudio
Inscripción (Anticipado)
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Cervical Cancer Stage Ib2, II and III (Squamous carcinoma or adenocarcinoma)
- Cancer of the vault
- Cancer of the cervix which inadvertently underwent hysterectomy (inadequate surgery)
- Treated with curative intent with radical radio(chemo)therapy or NACT followed by radical radio(chemo)therapy and completed all curative treatment.
- Within 2 years post completion of treatment
- Has complete clinical response at 3 months post treatment
- Informed consent
- Contactable by telephone
Exclusion Criteria:
- Patients with Stage III disease treated with palliative intent with once monthly radiotherapy
- Early stage cervical cancer patients who underwent Wertheims hysterectomy and who have completed adjuvant radiochemotherapy due to high-risk factors
- Metastatic cervical cancers
- Patients who are unable to comprehend the questions or dialogue over telephone by medical staff.
- Patients who seem unreliable for follow up
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Accuracy of nurse-led telephonic interview for disease recurrence
Periodo de tiempo: 1 YEAR
|
To estimate the accuracy of nurse-led telephonic interview in identifying patients with symptoms suggestive of disease recurrence, in terms of sensitivity and specificity values
|
1 YEAR
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Accuracy of nurse-led telephonic interview for late toxicity of treatment
Periodo de tiempo: 1 YEAR
|
To estimate the accuracy of nurse-led telephonic interview in identifying patients with symptoms suggestive of late toxicity of treatment
|
1 YEAR
|
Acceptability of a nurse-led telephonic surveillance program using structured format (Form C).
Periodo de tiempo: 1 YEAR
|
To assess patients' acceptability of a nurse-led telephonic surveillance program (if found to be concordant with physical clinic visits)
|
1 YEAR
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Anticipado)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- TMH-1950
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer de cuello uterino en estadio IIIB
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)ReclutamientoAdenocarcinoma de próstata | Cáncer de próstata en estadio IIIB AJCC v8 | Cáncer de próstata en estadio IIIC AJCC v8Estados Unidos
-
Thomas Jefferson UniversitySuspendidoAdenocarcinoma de próstata | Cáncer de próstata en estadio IIIB AJCC v8 | Cáncer de próstata en estadio IIIC AJCC v8Estados Unidos
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminadoAdenocarcinoma de intestino delgado | Adenocarcinoma de intestino delgado en estadio III AJCC v8 | Adenocarcinoma de intestino delgado en estadio IIIA AJCC v8 | Adenocarcinoma de intestino delgado en estadio IIIB AJCC v8 | Adenocarcinoma de intestino delgado en estadio IV AJCC v8 | Ampolla de... y otras condicionesEstados Unidos
-
Jonsson Comprehensive Cancer CenterJanssen Scientific Affairs, LLCAún no reclutandoAdenocarcinoma de próstata | Cáncer de próstata en estadio II AJCC v8 | Cáncer de próstata en estadio IIIA AJCC v8 | Cáncer de próstata en estadio IIIB AJCC v8Estados Unidos
-
Thomas Jefferson UniversityAún no reclutandoCarcinoma de próstata metastásico | Cáncer de próstata en estadio IV AJCC v8 | Cáncer de próstata en estadio IIIB AJCC v8 | Cáncer de próstata en estadio IIIC AJCC v8Estados Unidos
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationRetiradoCáncer de próstata en estadio III | Cáncer de próstata en estadio IV | Cáncer de próstata en estadio IVA | Cáncer de próstata en estadio IVB | Cáncer de próstata en estadio IIIA | Cáncer de próstata en estadio IIIB | Cáncer de próstata en estadio IIIC
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminadoAdenocarcinoma de la unión gastroesofágica | Cáncer de esófago en estadio IIA AJCC v7 | Cáncer de esófago en estadio IIB AJCC v7 | Cáncer de esófago en estadio IIIA AJCC v7 | Cáncer de esófago en estadio IIIB AJCC v7 | Cáncer de esófago en estadio IIIC AJCC v7 | Neoplasia maligna del esófago cervical y otras condicionesEstados Unidos
-
Emory UniversityNational Cancer Institute (NCI)ReclutamientoCáncer de próstata en estadio IIIA AJCC v8 | Cáncer de próstata en estadio IIIB AJCC v8 | Cáncer de próstata en estadio III AJCC v8 | Cáncer de próstata en estadio IIIC AJCC v8Estados Unidos
-
Marc Dall'Era, MDNational Cancer Institute (NCI)ReclutamientoCarcinoma de próstata localizado | Cáncer de próstata en estadio I AJCC v8 | Cáncer de próstata en estadio II AJCC v8 | Cáncer de próstata en estadio IIIA AJCC v8 | Cáncer de próstata en estadio IIIB AJCC v8Estados Unidos
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminadoAdenocarcinoma de próstata | Cáncer de próstata en estadio IIIA AJCC v8 | Cáncer de próstata en estadio IIIB AJCC v8 | Cáncer de próstata en estadio III AJCC v8 | Cáncer de próstata en estadio IIIC AJCC v8 | Testosterona superior a 150 ng/dLEstados Unidos